Certara, Inc. (NASDAQ:CERT) Short Interest Update

Certara, Inc. (NASDAQ:CERT) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 4,960,000 shares, a decline of 7.5% from the October 31st total of 5,360,000 shares. Approximately 4.5% of the shares of the company are short sold. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is presently 3.8 days.

Insider Buying and Selling at Certara

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. The trade was a 33.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. This trade represents a 9.75 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Certara

A number of large investors have recently bought and sold shares of CERT. Barclays PLC grew its position in shares of Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company’s stock valued at $825,000 after purchasing an additional 46,880 shares during the last quarter. Jane Street Group LLC grew its holdings in Certara by 2.6% in the 3rd quarter. Jane Street Group LLC now owns 147,393 shares of the company’s stock valued at $1,726,000 after buying an additional 3,732 shares during the last quarter. State Street Corp increased its position in Certara by 3.4% in the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company’s stock worth $43,089,000 after buying an additional 122,411 shares during the period. Petrus Trust Company LTA acquired a new position in shares of Certara during the third quarter worth approximately $994,000. Finally, Paloma Partners Management Co bought a new stake in shares of Certara in the third quarter valued at approximately $413,000. 73.96% of the stock is currently owned by institutional investors.

Certara Stock Down 2.7 %

Shares of NASDAQ CERT traded down $0.30 during mid-day trading on Wednesday, reaching $10.96. The company had a trading volume of 924,798 shares, compared to its average volume of 808,562. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. Certara has a twelve month low of $9.41 and a twelve month high of $19.87. The stock’s 50 day moving average is $10.82 and its 200-day moving average is $12.94. The stock has a market capitalization of $1.76 billion, a PE ratio of -56.30, a price-to-earnings-growth ratio of 5.71 and a beta of 1.53.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.06 EPS. As a group, equities analysts anticipate that Certara will post 0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on CERT. Barclays decreased their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Robert W. Baird reduced their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.